Personalis, Inc.PSNLEarnings & Financial Report
Personalis, Inc. is a precision medicine company specializing in advanced oncology genomics solutions. It develops proprietary genomic sequencing and data analytics platforms to support biopharmaceutical partners in immunotherapy development and clinical providers in delivering personalized cancer care, with operations spanning North America, Europe and key Asia-Pacific markets.
PSNL Q4 FY2025 Key Financial Metrics
Revenue
$17.3M
Gross Profit
$1.9M
Operating Profit
$-25.3M
Net Profit
$-23.8M
Gross Margin
11.0%
Operating Margin
-145.7%
Net Margin
-137.3%
YoY Growth
3.2%
EPS
$-0.26
Personalis, Inc. Q4 FY2025 Financial Summary
Personalis, Inc. reported revenue of $17.3M (up 3.2% YoY) for Q4 FY2025, with a net profit of $-23.8M (down 45.0% YoY) (-137.3% margin). Cost of goods sold was $15.4M, operating expenses totaled $27.2M.
Key Financial Metrics
| Total Revenue | $17.3M |
|---|---|
| Net Profit | $-23.8M |
| Gross Margin | 11.0% |
| Operating Margin | -145.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Personalis, Inc. Q4 FY2025 revenue of $17.3M breaks down across 2 segments, led by Population Sequencing at $11.8M (67.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Population Sequencing | $11.8M | 67.8% |
| Related Party | $5.4M | 31.1% |
Personalis, Inc. Revenue by Segment — Quarterly Trend
Personalis, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Population Sequencing and Related Party) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Population Sequencing | $11.8M | — | $3.3M | $4.2M |
| Related Party | $5.4M | $1.1M | — | — |
Personalis, Inc. Annual Revenue by Year
Personalis, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $69.6M).
Personalis, Inc. Quarterly Revenue & Net Profit History
Personalis, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.3M | +3.2% | $-23.8M | -137.3% |
| Q3 FY2025 | $14.5M | -43.6% | $-21.7M | -149.4% |
| Q2 FY2025 | $17.2M | -23.8% | $-20.1M | -116.6% |
| Q1 FY2025 | $20.6M | +5.5% | $-15.8M | -76.4% |
| Q4 FY2024 | $16.8M | -14.6% | $-16.4M | -97.8% |
| Q3 FY2024 | $25.7M | +40.9% | $-39.1M | -152.0% |
| Q2 FY2024 | $22.6M | +35.2% | $-12.8M | -56.7% |
| Q1 FY2024 | $19.5M | +3.5% | $-13.0M | -66.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $22.6M | $25.7M | $16.8M | $20.6M | $17.2M | $14.5M | $17.3M |
| YoY Growth | 3.5% | 35.2% | 40.9% | -14.6% | 5.5% | -23.8% | -43.6% | 3.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $195.3M | $185.5M | $239.9M | $270.3M | $273.3M | $258.7M | $242.8M | $334.2M |
| Liabilities | $74.6M | $73.2M | $73.1M | $67.3M | $66.0M | $67.9M | $71.4M | $73.0M |
| Equity | $120.7M | $112.3M | $166.8M | $203.0M | $207.3M | $190.8M | $171.4M | $261.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.4M | $-10.7M | $-6.2M | $-7.8M | $-18.0M | $-12.9M | $-21.8M | $-22.2M |